Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Neuromodulators in Refractory Functional Dyspepsia
NCT05099913Unknown
- Sponsor
- Renji Hospital
- Start
- Aug 2020
- Primary completion
- Oct 2022
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Trial of flupentixol + melitracen in functional dyspepsia (FD) (2 arms), sponsored by Renji Hospital. Primary endpoints: Leeds Dyspepsia Questionnaire at 4 weeks, Patient Health Questionnaire-9 at 4 weeks and 1 more. Status: unknown.
02
Drugs
flupentixol + melitracen
03
Conditions
functional dyspepsia (FD)
Beyond the preview
Go deeper on NCT05099913.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05099913.